PPA
TRML

Parametric Portfolio Associates’s Tourmaline Bio TRML Stock Holding History

Parametric Portfolio Associates’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,693
Closed -$230K – 3700
2021
Q3 		$230K Buy
+1,693
New +$232K ﹤0.01% 3392

Other funds holding TRML

Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Parametric Portfolio Associates's TRML Position: Q4 2021 in Review

Parametric Portfolio Associates sold out of Tourmaline Bio (TRML) in Q4 2021, closing a stake of 1,693 shares — an estimated $230K sold.

Parametric Portfolio Associates first reported a position in TRML in Q3 2021 and held it in 1 quarter. The position peaked at $230K in Q3 2021. 51 funds tracked by Wall St. Rank hold TRML as of Q4 2021.

  • Parametric Portfolio Associates reported no remaining Tourmaline Bio position as of Q4 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 1,693 Tourmaline Bio shares in Q4 2021, an estimated $230K.
  • Parametric Portfolio Associates first reported a position in Tourmaline Bio in Q3 2021 and held it in 1 quarter.
  • Parametric Portfolio Associates's Tourmaline Bio position peaked at $230K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2021.

Based on Parametric Portfolio Associates's 13F filing for Q4 2021, filed 15 Feb 2022.